Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2020 · 10-Q
Revenue$216.00K$216.00K−63.6% vs Q3 2019 Net Income-$194.10M-$194.10MN/M vs Q3 2019 EPS Diluted-$0.26-$0.26N/M vs Q3 2019 Operating Income-$47,877,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-22165.3%−21076.6 pt vs Q3 2019
Net margin-89859.3%−88806.6 pt vs Q3 2019
ended Sep 30, 2020 · filed Jan 15, 2021 · 107 d after period end